RELMADA THERAPEUTICS, INC. - 8-K Filing
Relmada Therapeutics appoints Jørn Skibsted Jakobsen, MD, PhD as Chief Development Officer to lead NDV-01 Phase 3 SPECTRUM program. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $RLMD